Congenital dysfibrinogenemia (CD) is a coagulation disorder caused by mutations in the fibrinogen gene, which result in abnormal fibrinogen function. Many studies have confirmed that over half of dysfibrinogenemia cases are Novel fibrinogen mutation and congenital dysfibrinogenemia asymptomatic. In this study, we aimed to investigate the pathogenesis of CD caused by γ Ala327Val heterozygous mutation, a new mutation, by studying fibrinogen function. Blood samples of patients were collected and the coagulation function, fibrinogen (Fg) aggregation test, fibrin clot lysis test, and SDS-PAGE were performed. Coagulation was monitored using a thromboelastometer, and the fibrin clot network structure was observed by scanning electron microscopy. The eff ect of the mutation on fibrinogen structure and function was predicted by molecular modeling. The fibrinogen activity concentration in patients with CD was significantly lower than that in healthy individuals.
Introduction
Fibrinogen (Fg), also known as coagulation factor I, is mainly produced by liver cells and is secreted into peripheral blood. Its plasma concentration is 2-4 g/L [1] . Fibrinogen is involved in the formation of fibrin clots and platelet aggregation, and plays an important role in hemostasis. At the initial stage of fibrin clot formation, fibrinogen binds to platelet membrane protein IIb/IIIa, activates platelets, and mediates platelet aggregation, thus participating in the coagulation process. The relative molecular weight of fibrinogen is 340 kD; it is composed of two identical subunits, each of which comprises three different polypeptide chains (A α, B β, and γ); these two subunits are linked by disulfide bonds [2] . Fibrinogen molecules have three major functional regions, the central region (E region) and two symmetric distal spherical D regions ( Figure 1 ). The three polypeptide chains A α, B β, and γ are encoded by FGA, FGB, and FGG genes (on chromosome 4), respectively [3] .
Mutations in FGA, FGB, or FGG may lead to the development of congenital dysfibrinogenemia (CD). CD is a congenital blood disease caused by Novel fibrinogen mutation and congenital dysfibrinogenemia defects in fibrinogen genes, which lead to abnormal structure and function of fibrinogen molecules, and may affect coagulation. The clinical manifestations of CD are diverse; most patients with CD are asymptomatic [4] , but a small number of patients with CD have thrombosis [5, 6] and bleeding events, and some patients have pulmonary hypertension and other symptoms [7] .
As most patients with CD are asymptomatic, and the single detection method used currently in clinical laboratories may lead to misdiagnosis or missed diagnosis, the incidence of CD is thus difficult to determine at present.
In this study, we identified a novel heterozygous mutation (FGG c.1058C > T ， γAla327Val) in an asymptomatic patient with abnormal fibrinogenemia. Functional studies of fibrinogen isolated from the patient and her family members were performed to study the molecular pathogenesis of CD caused by γ Ala327Val heterozygous missense mutation.
Methods

Basic data of patients and routine examination of coagulation function
The proband was a 45-year-old female patient. 
Scanning electron microscopy
The proband and healthy individuals were administered 33 μl of fibrinogen each, and thrombin was added at a final concentration of 2 
Modeling and analysis of amino acid mutation
The amino acid sequence of fibrinogen was obtained from the NCBI database, and a model of the fibrinogen structure was constructed using SWISS-MODEL website (https://swissmodel.expasy.org/)/.
Swiss-Pdb
Viewer software was used to analyze the effect of γ Ala327Val mutation on the function of fibrinogen.
Results
Routine coagulation function tests
The Results of the laboratory examination for the proband including electrolyte, liver and kidney function, and blood routine tests were normal.
Examination of these parameters for other members of the family showed that the coagulation results of the proband's sister, two brothers, and proband's daughter were similar to those of the proband, and there were no abnormalities in the results of the electrolyte, liver and kidney function, 1058C > T, γ Ala327Val) in exon 8 of the fibrinogen gene was found in the proband and her family members ( Figure 2 ).
Fibrinogen aggregation test
Compared with the healthy individuals, the OD values of fibrinogen aggregation curves for fibrinogen isolated from the proband and her family members were changed slightly, and the maximum OD values from 5 patients (average 0.283) were lower than those of the healthy individual (0.422) ( Figure 3) .
Fibrin clot dissolution test
The clot turbidity began to decrease after 496 seconds on average (healthy individuals: after 660 seconds). There was no fibrinolysis delay and resistance during clot dissolution (Figure 4 ).
Thromboelastography
The Figure 5 and Table 2 .
SDS-PAGE
The SDS-PAGE results revealed that the proband and her family members did not show any variant protein bands ( Figure 6 ).
Ultrastructure of fibrin clot
Shown in Figure 7 (A) is the structure of the control fibrin clot under a scanning electron microscope. The diameter of the fiber filament was uniform, the fiber nodes were few, the arrangement was neat and compact, the fiber filament interweaved and overlapped to form a fiber network, the spatial structure was relatively dense, and the network pore size was small. (B) The fibrin clot network structure of the proband showed that the fiber filaments were of different thickness, arranged irregularly, and the ends of the fiber filaments were curled into a mass. The fiber network space structure was loose, the network aperture increased, and the fiber branch nodes were more than those in the healthy individual.
Modeling and analysis of amino acid mutations
In the molecular model of wild-type fibrinogen, γ Our aggregation test and thromboelastography results revealed that the proband and her family members had impaired fibrin aggregation.
The ultrastructure of the probands' fibrin clots was observed by scanning electron microscopy. The sizes of the filaments were different, the arrangement was irregular, the ends of the filaments were coiled, the fiber network was loose, the aperture of the network was enlarged, and there were many fiber nodes. Defects in the D:D interaction between adjacent fibrinogen molecules leads to easy lateral extension of the filament, resulting in an increase in branch points and formation of thinner filaments [15] . Substitution of γAla327 results in incorrect end-to-end location of fibrin monomers during aggregation, resulting in Novel fibrinogen mutation and congenital dysfibrinogenemia the increase in fiber branching. Further, during polymerization, normal fibrin monomers can combine with mutant monomers, resulting in inconsistent fiber diameter, irregular arrangement, looseness, and large mesh-like structure. Analysis of the mutant fibrin clot network showed that the fibrin clots with impaired D:D interaction (γArg275His, γArg275Cys and γArg375Gly) had more pores in the network structure, and that the network comprised many conical fibers and pores [16] . These results are similar to those of this study.
Sugo et al [14] suggested that the structure of fibrin clot might be related to the clinical phenotype, and the phenotype could be predicted by studying the ultrastructure and network structure of fibrin clot. Studies have shown that the dissolution rate of fibrin clot depends on the density of its structure rather than the diameter of fibrin fibers, and the loose fibrin network structure composed of crude fibers is easier to be decomposed than the dense fibrin network structure composed of fine fibers [17] . Patients with high fibrin density in the fibrin network have a higher risk of thrombotic events [18] .
In patients with thrombotic CD, such as fibrinogen in plasma of patients with CD will not be reduced.
Combination of multiple methods to detect fibrinogen can reduce the rate of misdiagnosis and missed diagnosis of CD. Our previous study showed that the combination of PT-derived method and Clauss method is helpful to screen CD [21] . In this study, in the proband, the concentration of fibrinogen activity was significantly lower than that of fibrinogen antigen (0.75 g/L vs 1.59 g/L, Proband.
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